Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6980139 | 0.91 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6976911 | 0.88 | OPRL1 (0.33) | KDM4ECYP1A2CYP2D6CYP2C19 | |
| SCHEMBL6976420 | 0.86 | DPP7 (0.40) | CYP2D6 | |
| SCHEMBL15304811 | 0.83 | CYP1A2 (0.35) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6979252 | 0.82 | EPHX2 (0.42) | KDM4EALDH1A1 | |
| SCHEMBL9975280 | 0.82 | KDM4E (0.35) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6976860 | 0.80 | TP53 (0.41) | ALDH1A1 | |
| SCHEMBL6980214 | 0.75 | CYP1A2 (0.42) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL6979441 | 0.74 | KDM4E (0.41) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 | |
| SCHEMBL14878205 | 0.73 | KDM4E (0.37) | KDM4ECYP1A2CYP2D6CYP2C19ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349857-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2013-01-08 | — | — | US | disclosed |
| US-8202879-B2 | Quinazoline derivatives having tyrosine kinase inhibitory activity | SHIONOGI & CO., LTD. (JP) | 2012-06-19 | — | — | US | disclosed |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2012-05-17 | — | — | US | disclosed |
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | SHIONOGI & CO., LTD. (JP) | 2009-06-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143414-A1 | Quinazoline Derivatives Having Tyrosine Kinase Inhibitory Activity | ERBB2, EGFR, ABL1 | KDM4E 2805/4885CYP1A2 1375/4885CYP2D6 1566/4885 |
| US-20120123114-A1 | QUINAZOLINE DERIVATIVES HAVING TYROSINE KINASE INHIBITORY ACTIVITY | ERBB2, EGFR, ABL1 | KDM4E 2805/4885CYP1A2 1375/4885CYP2D6 1566/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.